The haematopoietic GTPase RhoH modulates IL3 signalling through regulation of STAT activity and IL3 receptor expression
- Mehtap S Gündogdu†1,
- He Liu†2, 3,
- Daniela Metzdorf1,
- Dagmar Hildebrand1,
- Michael Aigner4,
- Klaus Aktories2,
- Klaus Heeg1 and
- Katharina F Kubatzky1Email author
© Gündogdu et al; licensee BioMed Central Ltd. 2010
Received: 7 January 2010
Accepted: 25 August 2010
Published: 25 August 2010
RhoH is a constitutively active member of the family of Rho GTPases. Its expression is restricted to the haematopoietic lineage, where it serves as a positive regulator for T cell selection and mast cell function and as a negative regulator for growth-related functions in other lineages. Here, we examined the activation of signal transducer and activator of transcription (STAT) proteins in response to stimulation with interleukin 3 (IL3).
Using the murine IL3-dependent cell line BaF3 we investigated the influence of RhoH protein expression levels on IL3-mediated cellular responses. RhoH overexpressing cells showed lower sensitivity to IL3 and decreased STAT5 activation. SiRNA-mediated repression of RhoH gene expression led to an increase in proliferation and STAT5 activity which correlated with an increased number of IL3 receptor α chain molecules, also known as CD123, expressed at the cell surface. Interestingly, these findings could be reproduced using human THP-1 cells as a model system for acute myeloid leukaemia, where low RhoH levels are known to be an unfavourable prognostic marker. Overexpression of RhoH on the other hand caused an induction of STAT1 activity and western blot analysis revealed that activated STAT1 is phosphorylated on Tyr701. STAT1 is known to induce apoptosis or cell cycle arrest and we detected an upregulation of cyclin-dependent kinase inhibitors (CDKI) p21 Cip1 and p27 Kip1 in RhoH overexpressing BaF3 cells.
We propose that RhoH functions as a negative regulator for IL3-induced signals through modulation of the JAK-STAT pathway. High levels of RhoH allow the IL3-dependent activation of STAT1 causing decreased proliferation through upregulation of p21 Cip1 and p27 Kip1 . Low RhoH levels on the other hand led to an upregulation of IL3-dependent cell growth, STAT5 activity and an increase of CD123 surface expression, linking RhoH to a CD123/STAT5 phenotype that has been described in AML patients.
acute myeloid leukaemia
bone marrow cells
cluster of differentiation
cyclin dependent kinase inhibitors
granulocyte macrophage-colony stimulating factor
hairy cell leukaemia
interferon regulatory factor
immune receptor tyrosine based activation motif
relative light units
signal transducer and activator of transcription
Rho GTPases belong to the superfamily of Ras GTPases  and function as molecular switches that control and integrate signal transduction pathways by linking receptor-derived signals to downstream signalling proteins [2–4]. The Rho subfamily of GTPases consists of 20 proteins, but only two members, Rac2 and RhoH, are specifically expressed in haematopoietic cells [5, 6]. RhoH is a GTPase deficient protein [7, 8] and its activity is presumably modulated through transcriptional regulation . Recently it was found that RhoH activity can also be regulated by tyrosine phosphorylation of its non-canonical immune receptor tyrosine activation motif (ITAM) . The protein was first discovered as a fusion transcript with the transcriptional repressor LAZ3/BCL6 in Non Hodgkin lymphoma cells . In a number of B cell malignancies, RhoH is mutated with high frequency through somatic hypermutation [10, 11]. In Hairy Cell Leukaemia (HCL) and Acute Myeloid Leukaemia (AML), RhoH was found to be underexpressed at the protein level [12, 13]. The function of RhoH has been investigated in various haematopoietic cells and RhoH is thought to mainly act as a negative regulator for processes such as proliferation, survival, migration and engraftment of haematopoietic progenitor cells . This is presumably due to the negative regulatory role RhoH has on Rac1 [7, 13, 15], although the exact mechanism remains to be elucidated. RhoH null mice showed impaired T cell differentiation due to defective T cell receptor signalling [9, 16]. However, other functions of RhoH have now become known that had not been obvious from the knock-out animals [17–19]. In mast cells, for example, RhoH positively regulates signalling through the FcεR . In neutrophils from patients suffering from chronic obstructive pulmonary disease  or cystic fibrosis , a GM-CSF-dependent upregulation of RhoH had been found. These data were corroborated using RhoH-deficient mice, showing that RhoH negatively regulates leukotriene production.
Here, we demonstrate that RhoH regulates interleukin 3 (IL3)-induced signalling through modulation of the activity of signal transducer and activator of transcription (STAT) proteins. Important functions of IL3 are the regulation of growth and early differentiation of haematopoietic progenitors  as well as the control of the terminal differentiation of basophils, mast cells and dendritic cells [21, 22]. Recent publications suggest a strong link between RhoH expression levels and B cell malignancies [12, 13]. We therefore used IL3-dependent BaF3 cells, a murine proB cell line, as a model system. These cells were shown to express comparatively low levels of RhoH . We show that overexpression of RhoH decreases IL3-induced proliferation and the activity of STAT5. The surface expression level of the IL3 receptor α-chain (CD123) is inversely correlated to the expression levels of RhoH. In RhoH-deficient cells, the STAT5-dependent gene interferon regulatory factor-1 (IRF-1) is upregulated, eventually leading to an upregulation of CD123. Interestingly, only BaF3 cells that overexpress RhoH are able to activate STAT1 after stimulation with IL3. This correlates with an upregulation of the STAT1-dependent cell cycle inhibitors p21 Cip1 and p27 Kip1 . Thus, our findings link the regulatory function of RhoH on proliferation to an interaction with the JAK-STAT signalling pathway.
RhoH regulates IL3-dependent cell proliferation
To investigate whether the overexpression of RhoH leads to changes in IL3 receptor-mediated signalling events, proliferative responses were tested using control cells and BaF3 cells overexpressing RhoH (Figure 1C). Cells were incubated with IL3 concentrations ranging from 0.001 to 1 ng/ml and factor-dependent growth was determined after 48 hours through measurement of cellular ATP (Cell Titer Glo, Promega). In RhoH cells, the ability to proliferate in response to IL3 was reduced to app. 30%. On the other hand, siRhoH cells proliferated better in response to IL3 achieving a growth rate of 160% compared to cells transduced with the empty vector. Thus, the expression level of RhoH regulates the ability of BaF3 cells to proliferate in response to IL3. To clarify whether these findings were specific for IL3, we repeated the experiment with BaF3 cells transduced with erythropoietin receptor (EpoR). EpoR cells, EpoR-RhoH cells and parental BaF3 cells were cultivated at Epo concentrations between 0.01 and 6.5 U/ml and cell viability was again determined after 48 h (Figure 1D). Interestingly, no differences in Epo-induced growth could be detected between EpoR and EpoR-RhoH cells. Parental BaF3 cells were not able to grow, as expected, since they do not express the EpoR. We therefore conclude that RhoH specifically regulates IL3-induced proliferation.
RhoH modulates IL3-induced STAT activation
Since STAT1 is known to mainly transduce apoptotic or cycle arrest-inducing signals, we investigated whether we could observe increased apoptosis in RhoH cells. Apoptosis was induced in control cells, RhoH cells or siRhoH cells through withdrawal of cytokine or treatment with apoptosis inducing agents such as doxorubicin or staurosporine. Apoptosis was then measured by FACS analysis and subsequent quantification of Annexin-V positive cells. However, no difference in the susceptibility of RhoH cells was found compared to control cells (Figure 2C).
Overexpression of RhoH leads to the upregulation of p21 Cip1 and p27 Kip1
Underexpression of RhoH enhances STAT5 activity
IL3 Receptor α-chain expression is negatively regulated by RhoH
The enhanced activation of STAT5 in cells that expressed low levels of RhoH could potentially be caused by more efficient downstream signalling events or by an increase in the expression of the ligand binding cell surface receptor, IL3Rα (CD123). We therefore determined the surface localisation of CD123 by FACS analysis using a PE-labelled CD123 antibody. Figure 4D shows that siRhoH cells express app. 25% more CD123 than control cells, while RhoH overexpressing cells show a decrease of CD123 expression of app. 50% as determined from three independent experiments.
Interestingly, it is known that a large number of AML patients show elevated expression of CD123 and hyperactivation of STAT5, which protects these cells from apoptosis . It was found previously that the transcription factor interferon regulatory factor-1 (IRF-1) is highly overexpressed in AML eventually leading to the upregulation of the IRF-1-dependent gene CD123 . Since IRF-1 expression can be induced by STAT5 , we checked whether we could detect an upregulation of IRF-1 in siRhoH cells. Indeed, IRF-1 expression was app. 200 fold higher in siRhoH cells compared to control cells (Figure 4E).
The acute monocytic leukaemia cell line THP-1 displays an siRhoH phenotype
Previous work has shown that RhoH is a negative regulator for growth, survival and cytoskeletal modifications . We show here that the expression level of RhoH modulates the activity of STAT transcription factors STAT5 and STAT1. In the IL3-dependent cell line BaF3, RhoH acts as a specific negative regulator of IL3, but not Epo-induced proliferation and silencing of RhoH gene expression allows the cells to proliferate faster in response to IL3.
The JAK-STAT pathway is a major signalling pathway of haematopoietic cells that links proliferative signals to the cell cycle machinery. In IL3-mediated signalling, STAT5 plays a major role in the regulation of proliferation, differentiation and anti-apoptotic signalling [25, 26]. We demonstrate that overexpression of RhoH leads to a decrease in the activity of STAT5, whereas silencing of RhoH expression causes an increased activity of STAT5 compared to control cells. No changes in the expression level of total STAT5 protein were detectable and we therefore conclude that RhoH does not modulate STAT5 activity through regulation of STAT5 expression levels. Most interestingly, we also could show a link between RhoH expression levels and changes in the surface expression of the ILR3 α-chain CD123.
It had previously been suggested that an elevated CD123 expression, as it can be found in patients with acute myeloid leukaemia (AML), may contribute to the increased proliferation of leukaemic blasts, hyperactivation of STAT5 and poor prognosis . Low expression levels of RhoH were recently described as yet another factor linked to poor patient prognosis . Our data now show that these two findings indeed might be connected. Because low RhoH expression leads to an increased STAT5 activity, STAT5 might then induce expression of the IRF-1 gene, which in turn allows an IRF-1-dependent upregulation of the CD123 gene, eventually leading to an increase in the surface levels of the protein.
Although the regulatory influence of RhoH on STAT5 activity would be sufficient to account for the differences in proliferation, we observed an additional mechanism by which RhoH negatively regulates IL3-induced growth, namely the activation of STAT1 in RhoH overexpressing cells. STAT1 is the key factor that transduces the antiproliferative effects of interferons  and activation of STAT1 coincides with cell cycle arrest or apoptosis. As a consequence, STAT1 knock-out mice develop tumours more rapidly [32, 33]. When we screened control cells and RhoH overexpressing cells for differences in their sensitivity towards apoptotic stimuli, we were not able to find any. However, siRhoH showed increased survival after cytokine deprivation and readdition of IL3 to starved cells induced a pool of rapidly growing cells, whereas parental cells did not recover (unpublished data).
It has been reported that STAT1 activation can lead to the upregulation of p21 Cip1 causing subsequent cell cycle arrest or apoptosis and a STAT1 DNA binding site was found in the p21 Cip1 promoter . Another member of this family, p27 Kip1 , was shown to be downregulated by IL3 and BCR-ABL . Interestingly, we found that p21 Cip1 and p27 Kip1 are both upregulated when RhoH is expressed, i.e. STAT1 is activated, and we suggest this as a RhoH-dependent mechanism that serves to regulate progression in the cell cycle. We propose a model, where the balance between proliferation and apoptosis is fine-tuned by the expression level of RhoH. While high levels of RhoH lead to increased STAT1 but reduced STAT5 activity, downregulation of RhoH expression activates STAT5-dependent proliferation and survival signals. It will be important to examine whether in IL3 sensitive, differentiating haematopoietic progenitor cells, the expression level of RhoH can regulate the balance between proliferation and cell cycle arrest or apoptosis. There was no obvious haematopoietic defect in RhoH-deficient animals, however, it is possible that the disturbed IL3-dependent signalling can be compensated by other cytokines. In addition, it is known that in B cells, RhoH is a target of somatic hypermutation and translocation which affects the expression of the protein . Nevertheless, RhoH-deficient animals did not develop lymphomas or show other B cell malignancies, which is a discrepancy that shows the limit of the animal model.
Two recent publications now link low RhoH protein levels to cancer [12, 13]. In AML, RhoH expression is low, causing high levels of active, GTP-bound Rac1 and eventually resistance to chemotherapeutic apoptosis . Our results indicate that other signalling pathways, such as STAT5 activation and high expression of the IL3-binding α chain, might additionally be modulated by RhoH and contribute to the disease. To understand the importance of RhoH for the development of haematopoietic malignancies, it will be crucial to establish a link between RhoH mutations, its expression on the protein level and the activity of signalling molecules such as STATs that are known to be upregulated in a number of myeloproliferative disorders [35, 36]. In addition, the JAK-STAT pathway plays a central role in cytokine-mediated signalling in haematopoiesis and the immune system. This pathway has not yet been discussed as a potential target of RhoH and it will therefore be interesting to see whether cytokine receptors other than IL3 are regulated through the expression level of RhoH.
Taken together, we show that the haematopoietic GTPase RhoH can modulate signalling through the JAK-STAT pathway. High levels of RhoH lead to preferential activation of STAT1 and reduced cell proliferation. While there were no changes in apoptosis detectable at high RhoH levels, we found a pronounced upregulation of p21 Cip1 and p27 Kip , two genes involved in cell cycle arrest. Low RhoH levels led to an upregulation of IL3-dependent cell growth, STAT5 activity and an upregulation of CD123 surface expression. This phenotype was also found in human monocytic THP-1 cells, suggesting that a correction of low RhoH expression levels might be beneficial for AML patients.
Stimulation with IL3 was performed with recombinant IL3 (Natutec, Frankfurt, Germany). BaF3 cells were obtained from DSMZ (Braunschweig, Germany). All data shown were performed at least in three independent experiments.
cDNAs cloning and sequencing
The puromycin resistance cassette was amplified by PCR from the vector pSilencer 5.1 U6 retro (Ambion, Austin, USA) and restriction sites for Sal-I and Xho-I were introduced. Sense primer puromycin resistance: 5'-GCT AAC GTC GAC CGG GTA GGG GAG GCG CT-3'; anti sense primer puromycin resistance: 5'-GCT AAT CTC GAG TCA GGC ACC GGG CTT GC-3'. The PCR product was cloned into the Sal-I restriction site of the pMX-IRES-CD4 vector . The resulting construct (pMX-IRES-CD4-Puro) was verified by sequence analysis. Full length murine RhoH was cloned into BamH-I and Not-I sites of the pMX-IRES-CD4-Puro vector. The resulting construct pMX-RhoH-IRES-CD4-Puro RhoH was verified by sequence analysis.
Cell culture reagents
BaF3 cells were maintained in RPMI1640 medium containing 10% FBS, 1% Pen/Strep and IL3 containing supernatant (0.5%) generated by the cell line X63Ag8-653 . THP-1 cells were cultivated in RPMI1640 medium containing 10% FBS and 1% Pen/Strep.
Retroviral vector transduction
Retroviral supernatants were generated and used to transduce the IL3-dependent pro-B cell line BaF3 as described . Briefly, six-well plates of 293-derived Phoenix eco cells were transiently transfected with cDNAs encoding for murine RhoH gene (pMX-IRES-CD4-Puro) or the empty vector (control). After 48 h, 750 μl of viral supernatant was added to 5×105 BaF3 cells and centrifuged for 120 min at 37 °C and 900 g in the presence of 16 μg of Polybrene (Sigma, Taufkirchen, Germany). Transduced cells were selected in the presence of 1.5 μg/ml puromycin and transfection efficiency was evaluated by FACS analysis of human CD4 expression (BD Biosciences, Germany). To generate siRNAs specific to mouse RhoH a silencing 21mer as described in  was cloned into the vector pSilencer 5.1 U6 (Ambion, Austin, USA). As a control, a scrambled sequence with no similarity to a mouse gene was used. After infection, transduced cells were selected in the presence of 1.5 μg/ml puromycin.
THP-1 cells were transiently transfected with the human HA-tagged RhoH cDNA containing vector pMX-IRES-GFP or the corresponding empty vector using Metafectene (Biontex, Martinsried, Germany) according to manufacturer's instructions.
For the intracellular analysis of phosphorylated STATs, cells were fixed with 4% PFA/PBS prior to overnight permeabilization with methanol. Phosphorylated STATs were detected using FITC-labelled pSTAT1 (Y701), pSTAT5 (Y694) antibodies or the respective isotype controls (BD Bioscience, Heidelberg, Germany). For the analysis of CD123 surface expression, cells were incubated for 45 min with PBS/2% FBS before labelling with murine CD123-PE or human CD123-APC antibodies (eBioscience, Frankfurt a.M, Germany), or the respective isotype controls (BD Biosciences, Heidelberg, Germany). Cells were analyzed on a FACS Canto (BD Biosciences, Heidelberg, Germany).
Measurement of Cell Viability
Cytokine-dependent growth was determined by quantification of cellular ATP using the Cell Titer Glo Assay (Promega, Madison, WI, USA). Cells were washed with RPMI and starved for 3 hours in the presence of 1 mg/ml BSA. 3.75 × 104 cells/ml were seeded in a 96 well plate with the corresponding cytokine concentrations. Cells were processed according to the manufacturer's protocol and luminescence was determined using a Lumistar Optima luminometer (BMG Labtech, Offenburg, Germany).
Annexin V Assay
Cells were depleted of IL3 for 3 hours and 2.5 × 105 BaF3 cells/ml were seeded in a 6-well plate. Cells were either incubated overnight in regular BaF3 cell medium, in the absence of IL3 or under other stress conditions, such as treatment with 1 μM doxorubicin or 1 μM staurosporine (Sigma, Taufkirchen, Germany). Cells were stained with Annexin-V and propidium iodide according to the Annexin-V-FLUOS kit protocol provided by the manufacturer (Roche, Penzberg, Germany). Apoptosis was quantified using a FACS Canto (BD Biosciences, Heidelberg, Germany).
Whole Cell Extracts and Immunoprecipitation
BaF3 cells were starved for 3 h without IL3 and FBS before stimulation of 1 × 107 cells with 50 ng/ml IL3. Cells were lysed in NP40 lysis buffer with protease and phosphatase inhibitors (Roche, Penzberg, Germany) and incubated for 45 min at 4°C. After centrifugation, lysates were immunoprecipitated overnight with 5 μl of STAT1 or STAT5 antibodies (Santa Cruz Biotechnology, Santa Cruz, USA) bound to Protein A/G Sepharose (Santa Cruz Biotechnology, Santa Cruz, USA). Samples were separated by 12% SDS-PAGE, transferred to nitrocellulose and incubated with the corresponding phospho-specific antibodies for STAT1 (701) or STAT5 (Y694) (Cell Signaling Technology, Danvers MA, USA) or total STAT1/STAT5, followed by incubation with HRP-coupled anti-rabbit antibody (Cell Signaling Technology, Danvers MA, USA) and detection by enhanced chemiluminescence.
Detection of proteins after western blotting of whole cell lysates (20 μg protein) was performed using antibodies directed against β-actin and p27 Kip1 (Cell Signaling Technology, Danvers MA, USA), p21 Cip1 , STAT5 or HA-tag (Santa Cruz Biotechnology, Santa Cruz, USA). Quantification of immunoblots was performed using the Image Analysis System Bioprofil (Fröbel, Germany) Bio ID software version v12.06. Signal intensity was calculated against the loading control and is presented as fold induction compared with the unstimulated control or cells transduced with the empty vector (mean ± SD; n ≥ 2). Statistical significance was assessed by using a paired 's t-test, with *P < 0.05, **P < 0.01 and ***P < 0.005.
Quantitative real-time PCR
Small-scale preparations of RNA were made from 1 × 106 cells using the High Pure RNA Isolation Kit (Roche, Penzberg, Germany). Total RNA was transcribed with First Strand cDNA Kit (Fermentas GmbH, St. Leon-Rot, Germany). Aliquots of the cDNA were used for quantitative PCR analysis using the 7900 HT Fast Real-Time PCR System (Applied Biosystems, Darmstadt, Germany) and the ABsolute QPCR SYBR Green Rox Mix (Abgene, Epson, UK). The following primers were used: murine gapdh sense 5'-TTC ACC ACC ATG GAG AAG GC-3' and antisense 5'-GGC ATG GAC TGT GGT CAT GA-3', human gapdh sense 5'-ACG GAT TTG GTC GTA TTG GGC-3' and antisense 5'-TTG ACG GTG CCA TGG AAT TTG-3', murine RhoH sense 5'-GCT ACT CTG TGG CCA ACC AT-3' and antisense 5'-AGG TCC CAC CTC TCT CTG GT-3', p27 sense 5'-AGG GCC AAC AGA ACA GAA GA-3' and antisense 5'-CTC CTG GCA GGC AAC TAA TC-3'and p21 sense 5'-GCA GAC CAG CCT GAC-3' and antisense 5'-GCA GGC AGC GTA TAT ACA GGA-3', murine IRF-1 sense 5'-GGA GAT GTT AGC CGG ACA CT-3', murine IRF-1 antisense 5'-TGC TGA CGA CAC ACG GTG A-3', human IRF-1 sense 5'-GCT GGA CAT CAA CAA AGG AT-3' and antisense 5'-TGG TCT TTC ACC TCC TCG AT-3'. Results were analyzed using the Abgene software. For further analysis, results were exported to Excel (Microsoft) and calculated by relative ddCt method. All results were normalised with respect to the reference gene GAPDH. Results were then normalised to control cells (mean ± SD; n≥ 2). Statistical significance was assessed using a paired 's t-test, with *P < 0.05, **P < 0.01 or with ***P < 0.005.
This work was supported by a grant from the Deutsche Forschungsgemeinschaft DFG and an Olympia Morata Habilitation Fellowship to K.F.K. We thank Prof. Dr. G. Schmidt (Freiburg) for cDNA of human RhoH, Prof. C. Brakebusch (Kopenhagen) for cDNA of murine RhoH and RhoH knock-out mice, Dr. M. Huber (Aachen) for the generous gift of IL3-producing X63Ag8-653 cells and Dr. M. Hug (Freiburg) for human Epo (Roche). We thank Gabriele Sonnenmoser and Daniela Cerny (Heidelberg) for excellent technical assistance.
- Madaule P, Axel R: A novel ras-related gene family. Cell. 1985, 41: 31-40. 10.1016/0092-8674(85)90058-3View ArticlePubMed
- Bar-Sagi D, Hall A: Ras and Rho GTPases: a family reunion. Cell. 2000, 103: 227-238. 10.1016/S0092-8674(00)00115-XView ArticlePubMed
- Vojtek AB, Der CJ: Increasing complexity of the Ras signaling pathway. J Biol Chem. 1998, 273: 19925-19928. 10.1074/jbc.273.32.19925View ArticlePubMed
- Etienne-Manneville S, Hall A: Rho GTPases in cell biology. Nature. 2002, 420: 629-635. 10.1038/nature01148View ArticlePubMed
- Dallery E, Galiegue-Zouitina S, Collyn-d'Hooghe M, Quief S, Denis C, Hildebrand MP, Lantoine D, Deweindt C, Tilly H, Bastard C: TTF, a gene encoding a novel small G protein, fuses to the lymphoma-associated LAZ3 gene by t(3;4) chromosomal translocation. Oncogene. 1995, 10: 2171-2178.PubMed
- Didsbury J, Weber RF, Bokoch GM, Evans T, Snyderman R: rac, a novel ras-related family of proteins that are botulinum toxin substrates. J Biol Chem. 1989, 264: 16378-16382.PubMed
- Li X, Bu X, Lu B, Avraham H, Flavell RA, Lim B: The hematopoiesis-specific GTP-binding protein RhoH is GTPase deficient and modulates activities of other Rho GTPases by an inhibitory function. Mol Cell Biol. 2002, 22: 1158-1171. 10.1128/MCB.22.4.1158-1171.2002PubMed CentralView ArticlePubMed
- Zohn IM, Campbell SL, Khosravi-Far R, Rossman KL, Der CJ: Rho family proteins and Ras transformation: the RHOad less traveled gets congested. Oncogene. 1998, 17: 1415-1438. 10.1038/sj.onc.1202181View ArticlePubMed
- Gu Y, Chae HD, Siefring JE, Jasti AC, Hildeman DA, Williams DA: RhoH GTPase recruits and activates Zap70 required for T cell receptor signaling and thymocyte development. Nat Immunol. 2006, 7: 1182-1190. 10.1038/ni1396View ArticlePubMed
- Fueller F, Kubatzky KF: The small GTPase RhoH is an atypical regulator of haematopoietic cells. Cell Commun Signal. 2008, 6: 6- 10.1186/1478-811X-6-6PubMed CentralView ArticlePubMed
- Pasqualucci L, Neumeister P, Goossens T, Nanjangud G, Chaganti RS, Kuppers R, Dalla-Favera R: Hypermutation of multiple proto-oncogenes in B-cell diffuse large-cell lymphomas. Nature. 2001, 412: 341-346. 10.1038/35085588View ArticlePubMed
- Galiegue-Zouitina S, Delestre L, Dupont C, Troussard X, Shelley CS: Underexpression of RhoH in Hairy Cell Leukemia. Cancer Res. 2008, 68: 4531-4540. 10.1158/0008-5472.CAN-07-5661View ArticlePubMed
- Iwasaki T, Katsumi A, Kiyoi H, Tanizaki R, Ishikawa Y, Ozeki K, Kobayashi M, Abe A, Matsushita T, Watanabe T: Prognostic implication and biological roles of RhoH in acute myeloid leukaemia. Eur J Haematol. 2008, 81: 454-460. 10.1111/j.1600-0609.2008.01132.xView ArticlePubMed
- Gu Y, Jasti AC, Jansen M, Siefring JE: RhoH, a hematopoietic-specific Rho GTPase, regulates proliferation, survival, migration, and engraftment of hematopoietic progenitor cells. Blood. 2005, 105: 1467-1475. 10.1182/blood-2004-04-1604View ArticlePubMed
- Chae HD, Lee KE, Williams DA, Gu Y: Cross-talk between RhoH and Rac1 in regulation of actin cytoskeleton and chemotaxis of hematopoietic progenitor cells. Blood. 2008, 111: 2597-2605. 10.1182/blood-2007-06-093237PubMed CentralView ArticlePubMed
- Dorn T, Kuhn U, Bungartz G, Stiller S, Bauer M, Ellwart J, Peters T, Scharffetter-Kochanek K, Semmrich M, Laschinger M: RhoH is important for positive thymocyte selection and T-cell receptor signaling. Blood. 2007, 109: 2346-2355. 10.1182/blood-2006-04-019034View ArticlePubMed
- Daryadel A, Yousefi S, Troi D, Schmid I, Schmidt-Mende J, Mordasini C, Dahinden CA, Ziemiecki A, Simon HU: RhoH/TTF negatively regulates leukotriene production in neutrophils. J Immunol. 2009, 182: 6527-6532. 10.4049/jimmunol.0803846View ArticlePubMed
- Oda H, Fujimoto M, Patrick MS, Chida D, Sato Y, Azuma Y, Aoki H, Abe T, Suzuki H, Shirai M: RhoH plays critical roles in Fc epsilon RI-dependent signal transduction in mast cells. J Immunol. 2009, 182: 957-962.View ArticlePubMed
- Yousefi S, Cooper PR, Mueck B, Potter SL, Jarai G: cDNA representational difference analysis of human neutrophils stimulated by GM-CSF. Biochem Biophys Res Commun. 2000, 277: 401-409. 10.1006/bbrc.2000.3678View ArticlePubMed
- Migliaccio G, Migliaccio AR, Visser JW: Synergism between erythropoietin and interleukin-3 in the induction of hematopoietic stem cell proliferation and erythroid burst colony formation. Blood. 1988, 72: 944-951.PubMed
- Lantz CS, Boesiger J, Song CH, Mach N, Kobayashi T, Mulligan RC, Nawa Y, Dranoff G, Galli SJ: Role for interleukin-3 in mast-cell and basophil development and in immunity to parasites. Nature. 1998, 392: 90-93. 10.1038/32190View ArticlePubMed
- Rodewald HR, Dessing M, Dvorak AM, Galli SJ: Identification of a committed precursor for the mast cell lineage. Science. 1996, 271: 818-822. 10.1126/science.271.5250.818View ArticlePubMed
- Liu X, Constantinescu SN, Sun Y, Bogan JS, Hirsch D, Weinberg RA, Lodish HF: Generation of mammalian cells stably expressing multiple genes at predetermined levels. Anal Biochem. 2000, 280: 20-28. 10.1006/abio.2000.4478View ArticlePubMed
- Chin YE, Kitagawa M, Su WC, You ZH, Iwamoto Y, Fu XY: Cell growth arrest and induction of cyclin-dependent kinase inhibitor p21 WAF1/CIP1 mediated by STAT1. Science. 1996, 272: 719-722. 10.1126/science.272.5262.719View ArticlePubMed
- Mui AL, Wakao H, O'Farrell AM, Harada N, Miyajima A: Interleukin-3, granulocyte-macrophage colony stimulating factor and interleukin-5 transduce signals through two STAT5 homologs. EMBO J. 1995, 14: 1166-1175.PubMed CentralPubMed
- Quelle FW, Sato N, Witthuhn BA, Inhorn RC, Eder M, Miyajima A, Griffin JD, Ihle JN: JAK2 associates with the beta c chain of the receptor for granulocyte-macrophage colony-stimulating factor, and its activation requires the membrane-proximal region. Mol Cell Biol. 1994, 14: 4335-4341.PubMed CentralView ArticlePubMed
- Mui AL, Wakao H, Kinoshita T, Kitamura T, Miyajima A: Suppression of interleukin-3-induced gene expression by a C-terminal truncated Stat5: role of Stat5 in proliferation. EMBO J. 1996, 15: 2425-2433.PubMed CentralPubMed
- Testa U, Riccioni R, Militi S, Coccia E, Stellacci E, Samoggia P, Latagliata R, Mariani G, Rossini A, Battistini A: Elevated expression of IL-3Ralpha in acute myelogenous leukemia is associated with enhanced blast proliferation, increased cellularity, and poor prognosis. Blood. 2002, 100: 2980-2988. 10.1182/blood-2002-03-0852View ArticlePubMed
- Guzman ML, Upchurch D, Grimes B, Howard DS, Rizzieri DA, Luger SM, Phillips GL, Jordan CT: Expression of tumor-suppressor genes interferon regulatory factor 1 and death-associated protein kinase in primitive acute myelogenous leukemia cells. Blood. 2001, 97: 2177-2179. 10.1182/blood.V97.7.2177View ArticlePubMed
- Tian SS, Tapley P, Sincich C, Stein RB, Rosen J, Lamb P: Multiple signaling pathways induced by granulocyte colony-stimulating factor involving activation of JAKs, STAT5, and/or STAT3 are required for regulation of three distinct classes of immediate early genes. Blood. 1996, 88: 4435-4444.PubMed
- Bromberg JF, Horvath CM, Wen Z, Schreiber RD, Darnell JE: Transcriptionally active Stat1 is required for the antiproliferative effects of both interferon alpha and interferon gamma. Proc Natl Acad Sci USA. 1996, 93: 7673-7678. 10.1073/pnas.93.15.7673PubMed CentralView ArticlePubMed
- Durbin JE, Hackenmiller R, Simon MC, Levy DE: Targeted disruption of the mouse Stat1 gene results in compromised innate immunity to viral disease. Cell. 1996, 84: 443-450. 10.1016/S0092-8674(00)81289-1View ArticlePubMed
- Meraz MA, White JM, Sheehan KC, Bach EA, Rodig SJ, Dighe AS, Kaplan DH, Riley JK, Greenlund AC, Campbell D: Targeted disruption of the Stat1 gene in mice reveals unexpected physiologic specificity in the JAK-STAT signaling pathway. Cell. 1996, 84: 431-442. 10.1016/S0092-8674(00)81288-XView ArticlePubMed
- Parada Y, Banerji L, Glassford J, Lea NC, Collado M, Rivas C, Lewis JL, Gordon MY, Thomas NS, Lam EW: BCR-ABL and interleukin 3 promote haematopoietic cell proliferation and survival through modulation of cyclin D2 and p27Kip1 expression. J Biol Chem. 2001, 276: 23572-23580. 10.1074/jbc.M101885200View ArticlePubMed
- Akala OO, Clarke MF: Hematopoietic stem cell self-renewal. Curr Opin Genet Dev. 2006, 16: 496-501. 10.1016/j.gde.2006.08.011View ArticlePubMed
- Lin TS, Mahajan S, Frank DA: STAT signaling in the pathogenesis and treatment of leukemias. Oncogene. 2000, 19: 2496-2504. 10.1038/sj.onc.1203486View ArticlePubMed
- Karasuyama H, Melchers F: Establishment of mouse cell lines which constitutively secrete large quantities of interleukin 2, 3, 4 or 5, using modified cDNA expression vectors. Eur J Immunol. 1988, 18: 97-104. 10.1002/eji.1830180115View ArticlePubMed
- Kubatzky KF, Liu W, Goldgraben K, Simmerling C, Smith SO, Constantinescu SN: Structural requirements of the extracellular to transmembrane domain junction for erythropoietin receptor function. J Biol Chem. 2005, 280: 14844-14854. 10.1074/jbc.M411251200View ArticlePubMed
This article is published under license to BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.